NCT03458117View on ClinicalTrials.gov

T-VEC in Non-melanoma Skin Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 19, 2018

Primary Completion Date

February 4, 2022

Study Completion Date

March 15, 2022

Conditions
Non-melanoma Skin CancerBasal Cell CarcinomaSquamous Cell CarcinomaCutaneous LymphomaMerkel Cell Carcinoma
Interventions
GENETIC

Talimogene Laherparepvec (T-VEC)

a modified herpes simplex virus-1 (HSV-1) containing the gene coding for human granulocyte macrophage colony-stimulating factor (GM-CSF)

Trial Locations (1)

8091

Department of Dermatology, University Hospital Zurich, Zurich

All Listed Sponsors
lead

University of Zurich

OTHER

NCT03458117 - T-VEC in Non-melanoma Skin Cancer | Biotech Hunter | Biotech Hunter